Fractyl Health Inc. Unveils Promising Preclinical Data on GLP-1-Based Gene Therapy for Obesity and Diabetes Prevention at ADA Scientific Sessions
Fractyl Health Inc., a company specializing in metabolic therapeutics, has announced that it will present new preclinical data from its Rejuva® Smart GLP-1™ pancreatic gene therapy platform. The presentation is scheduled to take place at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois, from June 20-23, 2025. The data will be shared in a poster session titled "Single-Dose GLP-1-Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat-Fed Mice." The presentation is set for June 22, 2025, from 12:30 p.m. to 1:30 p.m. The poster will be available on the Fractyl website following the session.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467786-en) on June 13, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。